ETV6 fusion genes in hematological malignancies: A review

Leukemia Research

Volumn 36, Issue 8, 2012, Pages 945-961

  De Braekeleer, Etienne ^a,b,c   Douet Guilbert, Nathalie ^a,b,c   Morel, Frédéric ^a,b,c   Le Bris, Marie Josée ^c   Basinko, Audrey ^a,b,c   De Braekeleer, Marc ^a,b,c  

^a UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^b French Blood Agency   (France)

^c CHU MORVAN   (France)

Author keywords

Acute lymphoblastic leukemia; Acute myeloblastic leukemia; ETV6; Fusion genes; Myelodysplastic syndrome; Myeloproliferative neoplasm

Indexed keywords

HELIX LOOP HELIX PROTEIN; HOMEODOMAIN PROTEIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ETV6;

CDX2 GENE; CHIC2 ETV6 FUSION GENE; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ETV6 ABL1 FUSION GENE; ETV6 ABL2 FUSION GENE; ETV6 ACSL6 FUSION GENE; ETV6 ARNT FUSION GENE; ETV6 BAZ2A FUSION GENE; ETV6 CDX2 FUSION GENE; ETV6 FCHO2 FUSION GENE; ETV6 FGFR3 FUSION GENE; ETV6 FLT3 FUSION GENE; ETV6 FRK FUSION GENE; ETV6 FUSION GENE; ETV6 GOT1 FUSION GENE; ETV6 IGH FUSION GENE; ETV6 JAK2 FUSION GENE; ETV6 LYN FUSION GENE; ETV6 MDS1 EV11 FUSION GENE; ETV6 MDS2 FUSION GENE; ETV6 NCOA2 FUSION GENE; ETV6 NTRK3 FUSION GENE; ETV6 PDGFRA FUSION GENE; ETV6 PDGFRB FUSION GENE; ETV6 PER1 FUSION GENE; ETV6 PTPRR FUSION GENE; ETV6 RUNX1 FUSION GENE; ETV6 STL FUSION GENE; ETV6 SYK FUSION GENE; EXON; FLT3 GENE; FUSION GENE; GENE FUNCTION; GENE INSERTION; GENE LOSS; GENE TRANSLOCATION; HEMATOLOGIC MALIGNANCY; HOMEOBOX GENE; HUMAN; LEUKEMOGENESIS; MN1 ETV6 FUSION GENE; MNX1 ETV6 FUSION GENE; NTRK3 GENE; PARTNER GENE; PAX5 ETV6 FUSION GENE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTO ONCOGENE; REPRESSOR GENE; REVIEW; TTL ETV6 FUSION GENE;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; GENES, HOMEOBOX; HEMATOLOGIC NEOPLASMS; HUMANS; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEINS C-ETS; RECEPTOR PROTEIN-TYROSINE KINASES; REPRESSOR PROTEINS; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC;

EID: 84862532344     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.04.010     Document Type: Review

References (225)

1. Solomon E., Borrow J., Goddard A.D. Chromosome aberrations and cancer. Science 1991, 254:1153-1160.
2. Rabbitts T.H. Chromosomal translocations in human cancer. Nature 1994, 372:143-149.
3. Rowley J.D. The role of chromosome translocations in leukemogenesis. Semin Hematol 1999, 36:59-72.
4. Konopka J.B., Watanabe S.M., Singer J.W., Collins S.J., Witte O.N. Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration. Proc Natl Acad Sci USA 1985, 82:1810-1814.
5. Groffen J., Stephenson J.R., Heisterkamp N., de Klein A., Bartram C.R., Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984, 36:93-99.
6. Golub T.R., Barker G.F., Lovett M., Gilliland D.G. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994, 77:307-316.
7. Wlodarska I., Mecucci C., Baens M., Marynen P., Van den B.H. ETV6 gene rearrangements in hematopoietic malignant disorders. Leuk Lymphoma 1996, 23:287-295.
8. Bohlander S.K. ETV6: a versatile player in leukemogenesis. Semin Cancer Biol 2005, 15:162-174.
9. Seth A., Ascione R., Fisher R.J., Mavrothalassitis G.J., Bhat N.K., Papas T.S. The ets gene family. Cell Growth Differ 1992, 3:327-334.
10. Baens M., Peeters P., Guo C., Aerssens J., Marynen P. Genomic organization of TEL: the human ETS-variant gene 6. Genome Res 1996, 6:404-413.
11. Mavrothalassitis G., Ghysdael J. Proteins of the ETS family with transcriptional repressor activity. Oncogene 2000, 19:6524-6532.
12. Wang L.C., Kuo F., Fujiwara Y., Gilliland D.G., Golub T.R., Orkin S.H. Yolk sac angiogenic defect and intra-embryonic apoptosis in mice lacking the Ets-related factor TEL. EMBO J 1997, 16:4374-4383.
13. Wang L.C., Swat W., Fujiwara Y., Davidson L., Visvader J., Kuo F., et al. The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow. Genes Dev 1998, 12:2392-2402.
14. Hock H., Meade E., Medeiros S., Schindler J.W., Valk P.J., Fujiwara Y., et al. Tel/Etv6 is an essential and selective regulator of adult hematopoietic stem cell survival. Genes Dev 2004, 18:2336-2341.
15. Fenrick R., Wang L., Nip J., Amann J.M., Rooney R.J., Walker-Daniels J., et al. TEL, a putative tumor suppressor, modulates cell growth and cell morphology of ras-transformed cells while repressing the transcription of stromelysin-1. Mol Cell Biol 2000, 20:5828-5839.
16. Rompaey L.V., Potter M., Adams C., Grosveld G. Tel induces a G1 arrest and suppresses Ras-induced transformation. Oncogene 2000, 19:5244-5250.
17. Lopez R.G., Carron C., Oury C., Gardellin P., Bernard O., Ghysdael J. TEL is a sequence-specific transcriptional repressor. J Biol Chem 1999, 274:30132-30138.
18. Chakrabarti S.R., Nucifora G. The leukemia-associated gene TEL encodes a transcription repressor which associates with SMRT and mSin3A. Biochem Biophys Res Commun 1999, 264:871-877.
19. Boccuni P., MacGrogan D., Scandura J.M., Nimer S.D. The human L(3)MBT polycomb group protein is a transcriptional repressor and interacts physically and functionally with TEL (ETV6). J Biol Chem 2003, 278:15412-15420.
20. Guidez F., Petrie K., Ford A.M., Lu H., Bennett C.A., MacGregor A., et al. Recruitment of the nuclear receptor corepressor N-CoR by the TEL moiety of the childhood leukemia-associated TEL-AML1 oncoprotein. Blood 2000, 96:2557-2561.
21. Golub T.R. TEL gene rearrangements in myeloid malignancy. Hematol Oncol Clin North Am 1997, 11:1207-1220.
22. Sato Y., Bohlander S.K., Kobayashi H., Reshmi S., Suto Y., Davis E.M., et al. Heterogeneity in the breakpoints in balanced rearrangements involving band 12p13 in hematologic malignancies identified by fluorescence in situ hybridization: TEL (ETV6) is involved in only one half. Blood 1997, 90:4886-4893.
23. Berger R., Le Coniat M., Lacronique V., Daniel M.T., Lessard M., Berthou C., et al. Chromosome abnormalities of the short arm of chromosome 12 in hematopoietic malignancies:a report including three novel translocations involving the TEL/ETV6 gene. Leukemia 1997, 11:1400-1403.
24. Vieira L., Marques B., Cavaleiro C., Ambrosio A.P., Jorge M., Neto A., et al. Molecular cytogenetic characterization of rearrangements involving 12p in leukemia. Cancer Genet Cytogenet 2005, 157:134-139.
25. Wang L., Hiebert S.W. TEL contacts multiple co-repressors and specifically associates with histone deacetylase-3. Oncogene 2001, 20:3716-3725.
26. De Braekeleer M., Morel F., Le Bris M.J., Herry A., Douet-Guilbert N. The MLL gene and translocations involving chromosomal band 11q23 in acute leukemia. Anticancer Res 2005, 25:1931-1944.
27. Meyer C., Schneider B., Jakob S., Strehl S., Attarbaschi A., Schnittger S., et al. The MLL recombinome of acute leukemias. Leukemia 2006, 20:777-784.
28. De Braekeleer E., Douet-Guilbert N., Morel F., Le Bris M.J., Ferec C., De Braekeleer M. RUNX1 translocations and fusion genes in malignant hemopathies. Future Oncol 2011, 7:77-91.
29. Wlodarska I., La Starza R., Baens M., Dierlamm J., Uyttebroeck A., Selleslag D., et al. Fluorescence in situ hybridization characterization of new translocations involving TEL (ETV6) in a wide spectrum of hematologic malignancies. Blood 1998, 91:1399-1406.
30. Odero M.D., Carlson K., Calasanz M.J., Lahortiga I., Chinwalla V., Rowley J.D. Identification of new translocations involving ETV6 in hematologic malignancies by fluorescence in situ hybridization and spectral karyotyping. Genes Chromosomes Cancer 2001, 31:134-142.
31. Tosi S., Giudici G., Mosna G., Harbott J., Specchia G., Grosveld G., et al. Identification of new partner chromosomes involved in fusions with the ETV6 (TEL) gene in hematologic malignancies. Genes Chromosomes Cancer 1998, 21:223-229.
32. Carroll M., Tomasson M.H., Barker G.F., Golub T.R., Gilliland D.G. The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proc Natl Acad Sci USA 1996, 93:14845-14850.
33. Jousset C., Carron C., Boureux A., Quang C.T., Oury C., Dusanter-Fourt I., et al. A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFR beta oncoprotein. EMBO J 1997, 16:69-82.
34. David M., Cross N.C., Burgstaller S., Chase A., Curtis C., Dang R., et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 2007, 109:61-64.
35. Asou N., Iwanaga E., Nanri T., Mitsuya H. Successful treatment with low-dose imatinib mesylate of therapy-related myeloid neoplasm harboring TEL-PDGFRB in a patient with acute promyelocytic leukemia. Haematologica 2010, 95:e1.
36. Lierman E., Cools J. TV6 and PDGFRB: a license to fuse. Haematologica 2007, 92:145-147.
37. Curtis C.E., Grand F.H., Waghorn K., Sahoo T.P., George J., Cross N.C. A novel ETV6-PDGFRB fusion transcript missed by standard screening in a patient with an imatinib responsive chronic myeloproliferative disease. Leukemia 2007, 21:1839-1841.
38. Apperley J.F., Gardembas M., Melo J.V., Russell-Jones R., Bain B.J., Baxter J., et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002, 347:481-487.
39. Tipirneni E., Buttar A., Brettler D., Miron P., Bathini V. Chronic myeloproliferative disorder with ETV6-PDGFRbeta fusion gene. Ann Hematol 2012, 91:637-638.
40. Tokita K., Maki K., Tadokoro J., Nakamura Y., Arai Y., Sasaki K., et al. Chronic idiopathic myelofibrosis expressing a novel type of TEL-PDGFRB chimaera responded to imatinib mesylate therapy. Leukemia 2007, 21:190-192.
41. Score J., Curtis C., Waghorn K., Stalder M., Jotterand M., Grand F.H., et al. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia 2006, 20:827-832.
42. Walz C., Curtis C., Schnittger S., Schultheis B., Metzgeroth G., Schoch C., et al. Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene. Genes Chromosomes Cancer 2006, 45:950-956.
43. Reiter A., Walz C., Cross N.C. Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders. Curr Drug Targets 2007, 8:205-216.
44. Curtis C.E., Grand F.H., Musto P., Clark A., Murphy J., Perla G., et al. Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia. Br J Haematol 2007, 138:77-81.
45. Kawagishi J., Kumabe T., Yoshimoto T., Yamamoto T. Structure, organization, and transcription units of the human alpha-platelet-derived growth factor receptor gene, PDGFRA. Genomics 1995, 30:224-232.
46. Irusta P.M., Luo Y., Bakht O., Lai C.C., Smith S.O., DiMaio D. Definition of an inhibitory juxtamembrane WW-like domain in the platelet-derived growth factor beta receptor. J Biol Chem 2002, 277:38627-38634.
47. Stover E.H., Chen J., Folens C., Lee B.H., Mentens N., Marynen P., et al. Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent. Proc Natl Acad Sci USA 2006, 103:8078-8083.
48. Euhus D.M., Timmons C.F., Tomlinson G.E. ETV6-NTRK3--Trk-ing the primary event in human secretory breast cancer. Cancer Cell 2002, 2:347-348.
49. Knezevich S.R., Garnett M.J., Pysher T.J., Beckwith J.B., Grundy P.E., Sorensen P.H. ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma. Cancer Res 1998, 58:5046-5048.
50. Eguchi M., Eguchi-Ishimae M., Tojo A., Morishita K., Suzuki K., Sato Y., et al. Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25). Blood 1999, 93:1355-1363.
51. Forghieri F., Morselli M., Potenza L., Maccaferri M., Pedrazzi L., Paolini A., et al. Chronic eosinophilic leukaemia with ETV6-NTRK3 fusion transcript in an elderly patient affected with pancreatic carcinoma. Eur J Haematol 2011, 86:352-355.
52. Kralik J.M., Kranewitter W., Boesmueller H., Marschon R., Tschurtschenthaler G., Rumpold H., et al. Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia. Diagn Pathol 2011, 6:19.
53. Eguchi M., Eguchi-Ishimae M. Absence of t(12;15) associated ETV6-NTRK3 fusion transcripts in pediatric acute leukemias. Med Pediatr Oncol 2001, 37:417.
54. Lannon C.L., Sorensen P.H. ETV6-NTRK3: a chimeric protein tyrosine kinase with transformation activity in multiple cell lineages. Semin Cancer Biol 2005, 15:215-223.
55. Stirewalt D.L., Radich J.P. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 2003, 3:650-665.
56. Gilliland D.G., Griffin J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002, 100:1532-1542.
57. Grand F.H., Iqbal S., Zhang L., Russell N.H., Chase A., Cross N.C. A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy. Exp Hematol 2007, 35:1723-1727.
58. Vu H.A., Xinh P.T., Masuda M., Motoji T., Toyoda A., Sakaki Y., et al. FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation. Leukemia 2006, 20:1414-1421.
59. Walz C., Erben P., Ritter M., Bloor A., Metzgeroth G., Telford N., et al. Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. Blood 2011, 118:2239-2242.
60. Rosnet O., Schiff C., Pebusque M.J., Marchetto S., Tonnelle C., Toiron Y., et al. Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood 1993, 82:1110-1119.
61. Mizuki M., Fenski R., Halfter H., Matsumura I., Schmidt R., Muller C., et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 2000, 96:3907-3914.
62. Papadopoulos P., Ridge S.A., Boucher C.A., Stocking C., Wiedemann L.M. The novel activation of ABL by fusion to an ets-related gene, TEL. Cancer Res 1995, 55:34-38.
63. Brunel V., Sainty D., Carbuccia N., Mozzicconacci M., Fernandez F., Simonetti J., et al. A TEL/ABL fusion gene on chromosome 12p13 in a case of Ph-, BCR-atypical CML. Leukemia 1996, 10. 2003-2003.
64. Golub T.R., Goga A., Barker G.F., Afar D.E., McLaughlin J., Bohlander S.K., et al. Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol 1996, 16:4107-4116.
65. Andreasson P., Johansson B., Carlsson M., Jarlsfelt I., Fioretos T., Mitelman F., et al. BCR/ABL-negative chronic myeloid leukemia with ETV6/ABL fusion. Genes Chromosomes Cancer 1997, 20:299-304.
66. Van Limbergen H., Beverloo H.B., van Drunen E., Janssens A., Hahlen K., Poppe B., et al. Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia. Genes Chromosomes Cancer 2001, 30:274-282.
67. Keung Y.K., Beaty M., Steward W., Jackle B., Pettnati M. Chronic myelocytic leukemia with eosinophilia, t(9;12)(q34;p13), and ETV6-ABL gene rearrangement: case report and review of the literature. Cancer Genet Cytogenet 2002, 138:139-142.
68. Lin H., Guo J.Q., Andreeff M., Arlinghaus R.B. Detection of dual TEL-ABL transcripts and a Tel-Abl protein containing phosphotyrosine in a chronic myeloid leukemia patient. Leukemia 2002, 16:294-297.
69. O'Brien S.G., Vieira S.A., Connors S., Bown N., Chang J., Capdeville R., et al. Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation. Blood 2002, 99:3465-3467.
70. La Starza R., Trubia M., Testoni N., Ottaviani E., Belloni E., Crescenzi B., et al. Clonal eosinophils are a morphologic hallmark of ETV6/ABL1 positive acute myeloid leukemia. Haematologica 2002, 87:789-794.
71. Barbouti A., Ahlgren T., Johansson B., Hoglund M., Lassen C., Turesson I., et al. Clinical and genetic studies of ETV6/ABL1-positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate. Br J Haematol 2003, 122:85-93.
72. Meyer-Monard S., Muhlematter D., Streit A., Chase A.J., Gratwohl A., Cross N.C.P., et al. Broad molecular screening of an unclassifiable myeloproliferative disorder reveals an unexpected ETV6/ABL1 fusion transcript. Leukemia 2005, 19:1096-1099.
73. Tirado C.A., Sebastian S., Moore J.O., Gong J.Z., Goodman B.K. Molecular and cytogenetic characterization of a novel rearrangement involving chromosomes 9, 12, and 17 resulting in ETV6 (TEL) and ABL fusion. Cancer Genet Cytogenet 2005, 157:74-77.
74. Mozziconacci M.J., Sainty D., Chabannon C. A fifteen-year cytogenetic remission following interferon treatment in a patient with an indolent ETV6-ABL positive myeloproliferative syndrome. Am J Hematol 2007, 82:688-689.
75. Kawamata N., Dashti A., Lu D., Miller B., Koeffler H.P., Schreck R., et al. Chronic phase of ETV6-ABL1 positive CML responds to imatinib. Genes Chromosomes Cancer 2008, 47:919-921.
76. Baeumler J., Szuhai K., Falkenburg J.H., van Schie M.L., Ottmann O.G., Nijmeijer B.A. Establishment and cytogenetic characterization of a human acute lymphoblastic leukemia cell line (ALL-VG) with ETV6/ABL1 rearrangement. Cancer Genet Cytogenet 2008, 185:37-42.
77. Nand R., Bryke C., Kroft S.H., Divgi A., Bredeson C., Atallah E. Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors. Leuk Res 2009, 33:1144-1146.
78. Kelly J.C., Shahbazi N., Scheerle J., Jahn J., Suchen S., Christacos N.C., et al. Insertion (12;9)(p13;q34q34): a cryptic rearrangement involving ABL1/ETV6 fusion in a patient with Philadelphia-negative chronic myeloid leukemia. Cancer Genet Cytogenet 2009, 192:36-39.
79. Zuna J., Zaliova M., Muzikova K., Meyer C., Lizcova L., Zemanova Z., et al. Acute leukemias with ETV6/ABL1 (TEL/ABL) fusion: poor prognosis and prenatal origin. Genes Chromosomes Cancer 2010, 49:873-884.
80. Malone A., Langabeer S., O'Marcaigh A., Storey L., Bacon C.L., Smith O.P. A doctor(s) dilemma: ETV6-ABL1 positive acute lymphoblastic leukaemia. Br J Haematol 2010, 151:101-102.
81. Perna F., Abdel-Wahab O., Levine R.L., Jhanwar S.C., Imada K., Nimer S.D. ETV6-ABL1-positive "chronic myeloid leukemia": clinical and molecular response to tyrosine kinase inhibition. Haematologica 2011, 96:342-343.
82. De Braekeleer E., Douet-Guilbert N., Rowe D., Bown N., Morel F., Berthou C., et al. ABL1 fusion genes in hematological malignancies: a review. Eur J Haematol 2011, 86:361-371.
83. Janssen J.W., Ridge S.A., Papadopoulos P., Cotter F., Ludwig W.D., Fonatsch C., et al. The fusion of TEL and ABL in human acute lymphoblastic leukaemia is a rare event. Br J Haematol 1995, 90:222-224.
84. Nilsson T., Andreasson P., Hoglund M., Fioretos T., Billstrom R., Garwicz S., et al. ETV6/ABL fusion is rare in Ph-negative chronic myeloid disorders. Leukemia 1998, 12:1167-1168.
85. Wang J.Y. Abl tyrosine kinase in signal transduction and cell-cycle regulation. Curr Opin Genet Dev 1993, 3:35-43.
86. Miao Y.J., Wang J.Y. Binding of A/T-rich DNA by three high mobility group-like domains in c-Abl tyrosine kinase. J Biol Chem 1996, 271:22823-22830.
87. McWhirter J.R., Wang J.Y. An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias. EMBO J 1993, 12:1533-1546.
88. Cazzaniga G., Tosi S., Aloisi A., Giudici G., Daniotti M., Pioltelli P., et al. The tyrosine kinase abl-related gene ARG is fused to ETV6 in an AML-M4Eo patient with a t(1;12)(q25;p13): molecular cloning of both reciprocal transcripts. Blood 1999, 94:4370-4373.
89. Iijima Y., Ito T., Oikawa T., Eguchi M., Eguchi-Ishimae M., Kamada N., et al. A new ETV6/TEL partner gene, ARG (ABL-related gene or ABL2), identified in an AML-M3 cell line with a t(1;12)(q25;p13) translocation. Blood 2000, 95:2126-2131.
90. Griesinger F., Janke A., Podleschny M., Bohlander S.K. Identification of an ETV6-ABL2 fusion transcript in combination with an ETV6 point mutation in a T-cell acute lymphoblastic leukaemia cell line. Br J Haematol 2002, 119:454-458.
91. Peeters P., Raynaud S.D., Cools J., Wlodarska I., Grosgeorge J., Philip P., et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 1997, 90:2535-2540.
92. Lacronique V., Boureux A., Valle V.D., Poirel H., Quang C.T., Mauchauffe M., et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997, 278:1309-1312.
93. Xia K., Mukhopadhyay N.K., Inhorn R.C., Barber D.L., Rose P.E., Lee R.S., et al. The cytokine-activated tyrosine kinase JAK2 activates Raf-1 in a p21ras-dependent manner. Proc Natl Acad Sci USA 1996, 93:11681-11686.
94. Yagasaki F., Wakao D., Yokoyama Y., Uchida Y., Murohashi I., Kayano H., et al. Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation. Cancer Res 2001, 61:8371-8374.
95. Keegan K., Johnson D.E., Williams L.T., Hayman M.J. Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3. Proc Natl Acad Sci USA 1991, 88:1095-1099.
96. Perez-Castro A.V., Wilson J., Altherr M.R. Genomic organization of the human fibroblast growth factor receptor 3 (FGFR3) gene and comparative sequence analysis with the mouse Fgfr3 gene. Genomics 1997, 41:10-16.
97. Kuno Y., Abe A., Emi N., Iida M., Yamamori T., Tanimoto M., et al. An atypical myelodysplastic syndrome with t(9;12)(q22;p12) and TEL gene rearrangement. Br J Haematol 1999, 106:570-571.
98. Hosoya N., Qiao Y., Hangaishi A., Wang L., Nannya Y., Sanada M., et al. Identification of a SRC-like tyrosine kinase gene, FRK, fused with ETV6 in a patient with acute myelogenous leukemia carrying a t(6;12)(q21;p13) translocation. Genes Chromosomes Cancer 2005, 42:269-279.
99. Brown M.T., Cooper J.A. Regulation, substrates and functions of src. Biochim Biophys Acta 1996, 1287:121-149.
100. Cance W.G., Craven R.J., Bergman M., Xu L., Alitalo K., Liu E.T. Rak, a novel nuclear tyrosine kinase expressed in epithelial cells. Cell Growth Differ 1994, 5:1347-1355.
101. Lee J., Wang Z., Luoh S.M., Wood W.I., Scadden D.T. Cloning of FRK, a novel human intracellular SRC-like tyrosine kinase-encoding gene. Gene 1994, 138:247-251.
102. Tanaka H., Takeuchi M., Takeda Y., Sakai S., Abe D., Ohwada C., et al. Identification of a novel TEL-Lyn fusion gene in primary myelofibrosis. Leukemia 2010, 24:197-200.
103. Yamanashi Y., Fukushige S., Semba K., Sukegawa J., Miyajima N., Matsubara K., et al. The yes-related cellular gene lyn encodes a possible tyrosine kinase similar to p56lck. Mol Cell Biol 1987, 7:237-243.
104. Lowell C.A. Src-family kinases: rheostats of immune cell signaling. Mol Immunol 2004, 41:631-643.
105. Xu Y., Harder K.W., Huntington N.D., Hibbs M.L., Tarlinton D.M. Lyn tyrosine kinase: accentuating the positive and the negative. Immunity 2005, 22:9-18.
106. Takeda Y., Nakaseko C., Tanaka H., Takeuchi M., Yui M., Saraya A., et al. Direct activation of STAT5 by ETV6-LYN fusion protein promotes induction of myeloproliferative neoplasm with myelofibrosis. Br J Haematol 2011, 153:589-598.
107. Romana S.P., Poirel H., Le Coniat M., Flexor M.A., Mauchauffé M., Jonveaux P., et al. High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia. Blood 1995, 86:4263-4269.
108. Park K.U., She C.J., Shin H.Y., Ahn H.S., Kim C.J., Cho B.K., et al. Low incidence of TEL/AML1 fusion and TEL deletion in Korean childhood acute leukemia by extra-signal fluorescence in situ hybridization. Cancer Genet Cytogenet 2001, 126:73-77.
109. Liang D.C., Shih L.Y., Yang C.P., Hung I.J., Liu H.C., Jaing T.H., et al. Frequencies of ETV6-RUNX1 fusion and hyperdiploidy in pediatric acute lymphoblastic leukemia are lower in far east than west. Pediatr Blood Cancer 2010, 55:430-433.
110. Rubnitz J.E., Pui C.H., Downing J.R. The role of TEL fusion genes in pediatric leukemias. Leukemia 1999, 13:6-13.
111. Borkhardt A., Cazzaniga G., Viehmann S., Valsecchi M.G., Ludwig W.D., Burci L., et al. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Munster Study Group. Blood 1997, 90:571-577.
112. Douet-Guilbert N., Morel F., Le Bris M.J., Herry A., Le Calvez G., Marion V., et al. Fluorescence in situ hybridization study of TEL/AML1 fusion in B-cell acute lymphoblastic leukemia (1984-2002). Cancer Genet Cytogenet 2003, 144:143-147.
113. De Braekeleer E., Basinko A., Douet-Guilbert N., Morel F., Le Bris M.J., Berthou C., et al. Cytogenetics in pre-B and B-cell acute lymphoblastic leukemia: a study of 208 patients diagnosed between 1981 and 2008. Cancer Genet Cytogenet 2010, 200:8-15.
114. Okuda T., van Deursen J., Hiebert S.W., Grosveld G., Downing J.R. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996, 84:321-330.
115. Ito Y. Oncogenic potential of the RUNX gene family: 'overview'. Oncogene 2004, 23:4198-4208.
116. Okuda T., Cai Z., Yang S., Lenny N., Lyu C.J., van Deursen J.M.A., et al. Expression of knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood 1998, 91:3134-3143.
117. North T.E., de Bruijn M.F., Stacy T., Talebian L., Lind E., Robin C., et al. Runx1 expression marks long-term repopulating hematopoietic stem cells in the midgestation mouse embryo. Immunity 2002, 16:661-672.
118. Kagoshima H., Shigesada K., Satake M., Ito Y., Miyoshi H., Ohki M., et al. The Runt domain identifies a new family of heteromeric transcriptional regulators. Trends Genet 1993, 9:338-341.
119. Tanaka T., Kurokawa M., Ueki K., Tanaka K., Imai Y., Mitani K., et al. The extracellular signal-regulated kinase pathway phosphorylates AML1, an acute myeloid leukemia gene product, and potentially regulates its transactivation ability. Mol Cell Biol 1996, 16:3967-3979.
120. Kanno T., Kanno Y., Chen L.F., Ogawa E., Kim W.Y., Ito Y. Intrinsic transcriptional activation-inhibition domains of the polyomavirus enhancer binding protein 2/core binding factor alpha subunit revealed in the presence of the beta subunit. Mol Cell Biol 1998, 18:2444-2454.
121. Zeng C., van Wijnen A.J., Stein J.L., Meyers S., Sun W., Shopland L., et al. Identification of a nuclear matrix targeting signal in the leukemia and bone-related AML/CBF-alpha transcription factors. Proc Natl Acad Sci USA 1997, 94:6746-6751.
122. Yamaguchi Y., Kurokawa M., Imai Y., Izutsu K., Asai T., Ichikawa M., et al. AML1 is functionally regulated through p300-mediated acetylation on specific lysine residues. J Biol Chem 2004, 279:15630-15638.
123. Golub T.R., Barker G.F., Bohlander S.K., Hiebert S.W., Ward D.C., Bray-Ward P., et al. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci USA 1995, 92:4917-4921.
124. Romana S.P., Mauchauffé M., Le Coniat M., Chumakov I., Le Paslier D., Berger R., et al. The t(12;21) of acute lymphoblastic leukemia results in a tel-aml1 gene fusion. Blood 1995, 85:3662-3670.
125. Zelent A., Greaves M., Enver T. Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia. Oncogene 2004, 23:4275-4283.
126. Tsuzuki S., Seto M., Greaves M., Enver T. Modeling first-hit functions of the t(12;21) TEL-AML1 translocation in mice. Proc Natl Acad Sci USA 2004, 101:8443-8448.
127. Bernardin F., Yang Y., Cleaves R., Zahurak M., Cheng L., Civin C.I., et al. TEL-AML1, expressed from t(12;21) in human acute lymphocytic leukemia, induces acute leukemia in mice. Cancer Res 2002, 62:3904-3908.
128. Zaliova M., Meyer C., Cario G., Vaskova M., Marschalek R., Stary J., et al. TEL/AML1-positive patients lacking TEL exon 5 resemble canonical TEL/AML1 cases. Pediatr Blood Cancer 2011, 56:217-225.
129. Buijs A., Sherr S., van Baal S., van Bezouw S., van der P.D., Geurts vK, et al. Translocation (12;22) (p13;q11) in myeloproliferative disorders results in fusion of the ETS-like TEL gene on 12p13 to the MN1 gene on 22q11. Oncogene 1995, 10:1511-1519.
130. Nakazato H., Shiozaki H., Zhou M., Nakatsu M., Motoji T., Mizoguchi H., et al. TEL/MN1 fusion in a de novo acute myeloid leukaemia-M2 patient who showed strong resistance to treatment. Br J Haematol 2001, 113:1079-1081.
131. Chen S., Xue Y., Zhu X., Wu Y., Pan J. Minimally differentiated acute myeloid leukemia with t(12;22)(p13;q11) translocation showing primary multidrug resistance and expressing multiple multidrug-resistant proteins. Acta Haematol 2007, 118:38-41.
132. Nofrini V., Berchicci L., La Starza R., Gorello P., Di Giacomo D., Arcioni F., et al. MN1-ETV6 fusion gene arising from MDS With 5q- Leuk Res 2011, 35:e123-e126.
133. van Wely K.H., Meester-Smoor M.A., Janssen M.J., Aarnoudse A.J., Grosveld G.C., Zwarthoff E.C. The MN1-TEL myeloid leukemia-associated fusion protein has a dominant-negative effect on RAR-RXR-mediated transcription. Oncogene 2007, 26:5733-5740.
134. Buijs A., Van Rompaey L., Molijn A.C., Davis J.N., Vertegaal A.C., Potter M.D., et al. The MN1-TEL fusion protein, encoded by the translocation (12;22)(p13;q11) in myeloid leukemia, is a transcription factor with transforming activity. Mol Cell Biol 2000, 20:9281-9293.
135. van Wely K.H., Molijn A.C., Buijs A., Meester-Smoor M.A., Aarnoudse A.J., Hellemons A., et al. The MN1 oncoprotein synergizes with coactivators RAC3 and p300 in RAR-RXR-mediated transcription. Oncogene 2003, 22:699-709.
136. Salomon-Nguyen F., Della-Valle V., Mauchauffe M., Busson-Le Coniat M., Ghysdael J., Berger R., et al. The t(1;12)(q21;p13) translocation of human acute myeloblastic leukemia results in a TEL-ARNT fusion. Proc Natl Acad Sci USA 2000, 97:6757-6762.
137. Otsubo K., Kanegane H., Eguchi M., Eguchi-Ishimae M., Tamura K., Nomura K., et al. ETV6-ARNT fusion in a patient with childhood T lymphoblastic leukemia. Cancer Genet Cytogenet 2010, 202:22-26.
138. Crews S.T. Control of cell lineage-specific development and transcription by bHLH-PAS proteins. Genes Dev 1998, 12:607-620.
139. Adelman D.M., Maltepe E., Simon M.C. Multilineage embryonic hematopoiesis requires hypoxic ARNT activity. Genes Dev 1999, 13:2478-2483.
140. Murga Penas E.M., Cools J., Algenstaedt P., Hinz K., Seeger D., Schafhausen P., et al. A novel cryptic translocation t(12;17)(p13;p12-p13) in a secondary acute myeloid leukemia results in a fusion of the ETV6 gene and the antisense strand of the PER1 gene. Genes Chromosomes Cancer 2003, 37:79-83.
141. Taruscio D., Zoraqi G.K., Falchi M., Iosi F., Paradisi S., Di F.B., et al. The human per1 gene: genomic organization and promoter analysis of the first human orthologue of the Drosophila period gene. Gene 2000, 253:161-170.
142. Raynaud S.D., Baens M., Grosgeorge J., Rodgers K., Reid C.D., Dainton M., et al. Fluorescence in situ hybridization analysis of t(3; 12)(q26; p13): a recurring chromosomal abnormality involving the TEL gene (ETV6) in myelodysplastic syndromes. Blood 1996, 88:682-689.
143. Mitelman F, Johansson B, Mertens F. Mitelman database of chromosome aberrations and gene fusions in cancer. 2011. http://cgap.nci.nih.gov/Chromosomes/Mitelman.
144. Peeters P., Wlodarska I., Baens M., Criel A., Selleslag D., Hagemeijer A., et al. Fusion of ETV6 to MDS1/EVI1 as a result of t(3;12)(q26;p13) in myeloproliferative disorders. Cancer Res 1997, 57:564-569.
145. Nishimura Y., Wada H., Mori A., Takatsuka H., Tamura A., Fujimori Y., et al. Detection of ETV6/MDS1/Evi-1 chimeric transcripts in a patient with acute myelocytic leukemia and t(3;12)(q26;p13). Int J Hematol 2000, 72:108-109.
146. Nakamura Y., Nakazato H., Sato Y., Furusawa S., Mitani K. Expression of the TEL/EVI1 fusion transcript in a patient with chronic myelogenous leukemia with t(3;12)(q26;p13). Am J Hematol 2002, 69:80-82.
147. Morishita K., Parker D.S., Mucenski M.L., Jenkins N.A., Copeland N.G., Ihle J.N. Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell 1988, 54:831-840.
148. Tosi S., Stilgenbauer S., Giudici G., Capalbo S., Specchia G., Liso V., et al. Reciprocal translocation t(12;13)(p13;q14) in acute nonlymphoblastic leukemia: report and cytogenetic analysis of two cases. Cancer Genet Cytogenet 1994, 77:106-110.
149. Chase A., Reiter A., Burci L., Cazzaniga G., Biondi A., Pickard J., et al. Fusion of ETV6 to the caudal-related homeobox gene CDX2 in acute myeloid leukemia with the t(12;13)(p13;q12). Blood 1999, 93:1025-1031.
150. Drummond F., Putt W., Fox M., Edwards Y.H. Cloning and chromosome assignment of the human CDX2 gene. Ann Hum Genet 1997, 61:393-400.
151. Rawat V.P., Cusan M., Deshpande A., Hiddemann W., Quintanilla-Martinez L., Humphries R.K., et al. Ectopic expression of the homeobox gene Cdx2 is the transforming event in a mouse model of t(12;13)(p13;q12) acute myeloid leukemia. Proc Natl Acad Sci USA 2004, 101:817-822.
152. Cazzaniga G., Daniotti M., Tosi S., Giudici G., Aloisi A., Pogliani E., et al. The paired box domain gene PAX5 is fused to ETV6/TEL in an acute lymphoblastic leukemia case. Cancer Res 2001, 61:4666-4670.
153. Strehl S., Konig M., Dworzak M.N., Kalwak K., Haas O.A. PAX5/ETV6 fusion defines cytogenetic entity dic(9;12)(p13;p13). Leukemia 2003, 17:1121-1123.
154. Behrendt H., Charrin C., Gibbons B., Harrison C.J., Hawkins J.M., Heerema N.A., et al. Dicentric (9;12) in acute lymphocytic leukemia and other hematological malignancies: report from a dic(9;12) study group. Leukemia 1995, 9:102-106.
155. Nutt S.L., Heavey B., Rolink A.G., Busslinger M. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature 1999, 401:556-562.
156. Nutt S.L., Morrison A.M., Dorfler P., Rolink A., Busslinger M. Identification of BSAP (Pax-5) target genes in early B-cell development by loss- and gain-of-function experiments. EMBO J 1998, 17:2319-2333.
157. Simmons H.M., Oseth L., Nguyen P., O'Leary M., Conklin K.F., Hirsch B. Cytogenetic and molecular heterogeneity of 7q36/12p13 rearrangements in childhood AML. Leukemia 2002, 16:2408-2416.
158. Tosi S., Hughes J., Scherer S.W., Nakabayashi K., Harbott J., Haas O.A., et al. Heterogeneity of the 7q36 breakpoints in the t(7;12) involving ETV6 in infant leukemia. Genes Chromosomes Cancer 2003, 38:191-200.
159. Beverloo H.B., Panagopoulos I., Isaksson M., van Wering E., van Drunen E., de Klein A., et al. Fusion of the homeobox gene HLXB9 and the ETV6 gene in infant acute myeloid leukemias with the t(7;12)(q36;p13). Cancer Res 2001, 61:5374-5377.
160. von Bergh A.R., van Drunen E., van Wering E.R., van Zutven L.J., Hainmann I., Lonnerholm G., et al. High incidence of t(7;12)(q36;p13) in infant AML but not in infant ALL, with a dismal outcome and ectopic expression of HLXB9. Genes Chromosomes Cancer 2006, 45:731-739.
161. Hauer J., Tosi S., Schuster F.R., Harbott J., Kolb H.J., Borkhardt A. Graft versus leukemia effect after haploidentical HSCT in a MLL-negative infant AML with HLXB9/ETV6 rearrangement. Pediatr Blood Cancer 2008, 50:921-923.
162. Taketani T., Taki T., Sako M., Ishii T., Yamaguchi S., Hayashi Y. MNX1-ETV6 fusion gene in an acute megakaryoblastic leukemia and expression of the MNX1 gene in leukemia and normal B cell lines. Cancer Genet Cytogenet 2008, 186:115-119.
163. Deguchi Y., Kehrl J.H. Selective expression of two homeobox genes in CD34-positive cells from human bone marrow. Blood 1991, 78:323-328.
164. Deguchi Y., Yamanaka Y., Theodossiou C., Najfeld V., Kehrl J.H. High expression of two diverged homeobox genes, HB24 and HB9, in acute leukemias: molecular markers of hematopoietic cell immaturity. Leukemia 1993, 7:446-451.
165. Park J., Kim M., Lim J., Kim Y., Han K., Lee J., et al. Three-way complex translocations in infant acute myeloid leukemia with t(7;12)(q36;p13): the incidence and correlation of a HLXB9 overexpression. Cancer Genet Cytogenet 2009, 191:102-105.
166. Harada H., Harada Y., Eguchi M., Dohy H., Kamada N. Characterization of acute leukemia with t(4;12). Leuk Lymphoma 1997, 25:47-53.
167. Cools J., Bilhou-Nabera C., Wlodarska I., Cabrol C., Talmant P., Bernard P., et al. Fusion of a novel gene, BTL, to ETV6 in acute myeloid leukemias with a t(4;12)(q11-q12;p13). Blood 1999, 94:1820-1824.
168. Cools J., Mentens N., Odero M.D., Peeters P., Wlodarska I., Delforge M., et al. Evidence for position effects as a variant ETV6-mediated leukemogenic mechanism in myeloid leukemias with a t(4;12)(q11-q12;p13) or t(5;12)(q31;p13). Blood 2002, 99:1776-1784.
169. Kuchenbauer F., Schoch C., Holler E., Haferlach T., Hiddemann W., Schnittger S. A rare case of acute myeloid leukemia with a CHIC2-ETV6 fusiongen and multiple other molecular aberrations. Leukemia 2005, 19:2366-2368.
170. Chen B., Zhao W.L., Jin J., Xue Y.Q., Cheng X., Chen X.T., et al. Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries. Leukemia 2005, 19:767-775.
171. Silva F.P., Morolli B., Storlazzi C.T., Zagaria A., Impera L., Klein B., et al. ETV6 mutations and loss in AML-M0. Leukemia 2008, 22:1639-1643.
172. Cools J., Mentens N., Marynen P. A new family of small, palmitoylated, membrane-associated proteins, characterized by the presence of a cysteine-rich hydrophobic motif. FEBS Lett 2001, 492:204-209.
173. Hsieh-Li H.M., Witte D.P., Szucsik J.C., Weinstein M., Li H., Potter S.S. Gsh-2, a murine homeobox gene expressed in the developing brain. Mech Dev 1995, 50:177-186.
174. Brooke N.M., Garcia-Fernandez J., Holland P.W. The ParaHox gene cluster is an evolutionary sister of the Hox gene cluster. Nature 1998, 392:920-922.
175. van Oostveen J., Bijl J., Raaphorst F., Walboomers J., Meijer C. The role of homeobox genes in normal hematopoiesis and hematological malignancies. Leukemia 1999, 13:1675-1690.
176. Odero M.D., Vizmanos J.L., Roman J.P., Lahortiga I., Panizo C., Calasanz M.J., et al. A novel gene, MDS2, is fused to ETV6/TEL in a t(1;12)(p36. 1;p13) in a patient with myelodysplastic syndrome. Genes Chromosomes Cancer 2002, 35:11-19.
177. Dai M.S., Sears R., Lu H. Feedback regulation of c-Myc by ribosomal protein L11. Cell Cycle 2007, 6:2735-2741.
178. Dai M.S., Arnold H., Sun X.X., Sears R., Lu H. Inhibition of c-Myc activity by ribosomal protein L11. EMBO J 2007, 26:3332-3345.
179. Zhang Y., Wolf G.W., Bhat K., Jin A., Allio T., Burkhart W.A., et al. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol Cell Biol 2003, 23:8902-8912.
180. Boria I., Garelli E., Gazda H.T., Aspesi A., Quarello P., Pavesi E., et al. The ribosomal basis of Diamond-Blackfan Anemia: mutation and database update. Hum Mutat 2010, 31:1269-1279.
181. Coignet L.J., Lima C.S., Min T., Streubel B., Swansbury J., Telford N., et al. Myeloid- and lymphoid-specific breakpoint cluster regions in chromosome band 13q14 in acute leukemia. Genes Chromosomes Cancer 1999, 25:222-229.
182. Qiao Y., Ogawa S., Hangaishi A., Yuji K., Izutsu K., Kunisato A., et al. Identification of a novel fusion gene, TTL, fused to ETV6 in acute lymphoblastic leukemia with t(12;13)(p13;q34), and its implication in leukemogenesis. Leukemia 2003, 17:1112-1120.
183. Zhang L.Q., Downie P.A., Goodell W.R., McCabe N.R., LeBeau M.M., Morgan R., et al. Establishment of cell lines from B-cell precursor acute lymphoblastic leukemia. Leukemia 1993, 7:1865-1874.
184. Kobayashi H., Montgomery K.T., Bohlander S.K., Adra C.N., Lim B.L., Kucherlapati R.S., et al. Fluorescence in situ hybridization mapping of translocations and deletions involving the short arm of human chromosome 12 in malignant hematologic diseases. Blood 1994, 84:3473-3482.
185. Suto Y., Sato Y., Smith S.D., Rowley J.D., Bohlander S.K. A t(6;12)(q23;p13) results in the fusion of ETV6 to a novel gene, STL, in a B-cell ALL cell line. Genes Chromosomes Cancer 1997, 18:254-268.
186. Nakamura F., Nakamura Y., Maki K., Sato Y., Mitani K. Cloning and characterization of the novel chimeric gene TEL/PTPRR in acute myelogenous leukemia with inv(12)(p13q13). Cancer Res 2005, 65:6612-6621.
187. Shiozuka K., Watanabe Y., Ikeda T., Hashimoto S., Kawashima H. Cloning and expression of PCPTP1 encoding protein tyrosine phosphatase. Gene 1995, 162:279-284.
188. Strehl S., Nebral K., Konig M., Harbott J., Strobl H., Ratei R., et al. ETV6-NCOA2: a novel fusion gene in acute leukemia associated with coexpression of T-lymphoid and myeloid markers and frequent NOTCH1 mutations. Clin Cancer Res 2008, 14:977-983.
189. Hong H., Kohli K., Garabedian M.J., Stallcup M.R. GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors. Mol Cell Biol 1997, 17:2735-2744.
190. Panagopoulos I., Strombeck B., Isaksson M., Heldrup J., Olofsson T., Johansson B. Fusion of ETV6 with an intronic sequence of the BAZ2A gene in a paediatric pre-B acute lymphoblastic leukaemia with a cryptic chromosome 12 rearrangement. Br J Haematol 2006, 133:270-275.
191. Jones M.H., Hamana N., Nezu J., Shimane M. A novel family of bromodomain genes. Genomics 2000, 63:40-45.
192. Janssen H., Wlodarska I., Mecucci C., Hagemeijer A., Vandenberghe P., Marynen P., et al. Fusion of ETV6 to GOT1 in a case with myelodysplastic syndrome and t(10;12)(q24;p13). Haematologica 2006, 91:949-951.
193. Struski S., Mauvieux L., Gervais C., Helias C., Liu K.L., Lessard M. ETV6/GOT1 fusion in a case of t(10;12)(q24;p13)-positive myelodysplastic syndrome. Haematologica 2008, 93:467-468.
194. Choudhury B.K., Setoyama C., Shimada K. Molecular cloning and sequence analysis of the human cytosolic aspartate aminotransferase gene. Biochem Int 1990, 22:583-591.
195. Rhee S., Silva M.M., Hyde C.C., Rogers P.H., Metzler C.M., Metzler D.E., et al. Refinement and comparisons of the crystal structures of pig cytosolic aspartate aminotransferase and its complex with 2-methylaspartate. J Biol Chem 1997, 272:17293-17302.
196. Pan Q.W., Tanase S., Fukumoto Y., Nagashima F., Rhee S., Rogers P.H., et al. Functional roles of valine 37 and glycine 38 in the mobile loop of porcine cytosolic aspartate aminotransferase. J Biol Chem 1993, 268:24758-24765.
197. Belloni E., Trubia M., Mancini M., Derme V., Nanni M., Lahortiga I., et al. A new complex rearrangement involving the ETV6, LOC115548, and MN1 genes in a case of acute myeloid leukemia. Genes Chromosomes Cancer 2004, 41:272-277.
198. Aspenstrom P. A Cdc42 target protein with homology to the non-kinase domain of FER has a potential role in regulating the actin cytoskeleton. Curr Biol 1997, 7:479-487.
199. Greer P. Closing in on the biological functions of Fps/Fes and Fer. Nat Rev Mol Cell Biol 2002, 3:278-289.
200. Katoh M., Katoh M. Identification and characterization of human FCHO2 and mouse Fcho2 genes in silico. Int J Mol Med 2004, 14:327-331.
201. Katsura Y., Suzukawa K., Nanmoku T., Nemoto N., Machino T., Obara N., et al. Myelodysplastic syndrome accompanied by basophilia and eosinophilia with t(5;12)(q31;p13). Cancer Genet Cytogenet 2007, 178:85-88.
202. Malhotra K.T., Malhotra K., Lubin B.H., Kuypers F.A. Identification and molecular characterization of acyl-CoA synthetase in human erythrocytes and erythroid precursors. Biochem J 1999, 344(Pt 1):135-143.
203. Glick B.S., Rothman J.E. Possible role for fatty acyl-coenzyme A in intracellular protein transport. Nature 1987, 326:309-312.
204. Bronfman M., Orellana A., Morales M.N., Bieri F., Waechter F., Staubli W., et al. Potentiation of diacylglycerol-activated protein kinase C by acyl-coenzyme A thioesters of hypolipidaemic drugs. Biochem Biophys Res Commun 1989, 159:1026-1031.
205. Li Q.L., Yamamoto N., Inoue A., Morisawa S. Fatty acyl-CoAs are potent inhibitors of the nuclear thyroid hormone receptor in vitro. J Biochem 1990, 107:699-702.
206. Yagasaki F., Jinnai I., Yoshida S., Yokoyama Y., Matsuda A., Kusumoto S., et al. Fusion of TEL/ETV6 to a novel ACS2 in myelodysplastic syndrome and acute myelogenous leukemia with t(5;12)(q31;p13). Genes Chromosomes Cancer 1999, 26:192-202.
207. Murati A., Adelaide J., Gelsi-Boyer V., Etienne A., Remy V., Fezoui H., et al. t(5;12)(q23-31;p13) with ETV6-ACSL6 gene fusion in polycythemia vera. Leukemia 2006, 20:1175-1178.
208. Erben P., Gosenca D., Muller M.C., Reinhard J., Score J., Del Valle F., et al. Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis. Haematologica 2010, 95:738-744.
209. Yang Y.C., Ciarletta A.B., Temple P.A., Chung M.P., Kovacic S., Witek-Giannotti J.S., et al. Human IL-3 (multi-CSF): identification by expression cloning of a novel hematopoietic growth factor related to murine IL-3. Cell 1986, 47:3-10.
210. Chang J.M., Metcalf D., Lang R.A., Gonda T.J., Johnson G.R. Nonneoplastic hematopoietic myeloproliferative syndrome induced by dysregulated multi-CSF (IL-3) expression. Blood 1989, 73:1487-1497.
211. Perkins A., Kongsuwan K., Visvader J., Adams J.M., Cory S. Homeobox gene expression plus autocrine growth factor production elicits myeloid leukemia. Proc Natl Acad Sci USA 1990, 87:8398-8402.
212. Weller P.F. The immunobiology of eosinophils. N Engl J Med 1991, 324:1110-1118.
213. Lu X.Y., Harris C.P., Cooley L., Margolin J., Steuber P.C., Sheldon M., et al. The utility of spectral karyotyping in the cytogenetic analysis of newly diagnosed pediatric acute lymphoblastic leukemia. Leukemia 2002, 16:2222-2227.
214. Takeuchi S., Seriu T., Bartram C.R., Golub T.R., Reiter A., Miyoshi I., et al. TEL is one of the targets for deletion on 12p in many cases of childhood B-lineage acute lymphoblastic leukemia. Leukemia 1997, 11:1220-1223.
215. Sato Y., Suto Y., Pietenpol J., Golub T.R., Gilliland D.G., Davis E.M., et al. TEL and KIP1 define the smallest region of deletions on 12p13 in hematopoietic malignancies. Blood 1995, 86:1525-1533.
216. Baens M., Wlodarska I., Corveleyn A., Hoornaert I., Hagemeijer A., Marynen P. A physical, transcript, and deletion map of chromosome region 12p12.3 flanked by ETV6 and CDKN1B: hypermethylation of the LRP6 CpG island in two leukemia patients with hemizygous del(12p). Genomics 1999, 56:40-50.
217. Barjesteh van Waalwijk van Doorn-Khosrovani S., Spensberger D., de K.Y., Tang M., Lowenberg B., Delwel R. Somatic heterozygous mutations in ETV6 (TEL) and frequent absence of ETV6 protein in acute myeloid leukemia. Oncogene 2005, 24:4129-4137.
218. Bejar R., Stevenson K., Abdel-Wahab O., Galili N., Nilsson B., Garcia-Manero G., et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011, 364:2496-2506.
219. Steer E.J., Cross N.C. Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta. Acta Haematol 2002, 107:113-122.
220. Malfuson J.V., Konopacki J., Fagot T., Desangles F., Bories D., Souleau B., et al. Therapy-related myeloproliferative neoplasm with ETV6-PDGFRB rearrangement following treatment of acute promyelocytic leukemia. Ann Hematol 2011.
221. Crescenzi B., La Starza R., Nozzoli C., Ciolli S., Matteucci C., Romoli S., et al. Molecular cytogenetic findings in a four-way t(1;12;5;12)(p36;p13;q33;q24) underlying the ETV6-PDGFRB fusion gene in chronic myelomonocytic leukemia. Cancer Genet Cytogenet 2007, 176:67-71.
222. Nadal N., Flandrin P., Cornillon J., Delabesse E., Mauvieux L., Olaru D., et al. Successful treatment with imatinib mesylate in a case of chronic myeloproliferative disorder with a t(5;12)(q33;p13.1) without eosinophilia. Cancer Genet Cytogenet 2006, 169:174-175.
223. Wlodarska I., Mecucci C., Marynen P., Guo C., Franckx D., La Starza R., et al. TEL gene is involved in myelodysplastic syndromes with either the typical t(5;12)(q33;p13) translocation or its variant t(10;12)(q24;p13). Blood 1995, 85:2848-2852.
224. Yahata N., Ohyashiki K., Ohyashiki J.H., Kimura Y., Miyazawa K., Kodama A., et al. Late appearance of t(5;12)(q31;p12) in acute myeloid leukemia associated with eosinophilia. Cancer Genet Cytogenet 1998, 107:147-150.
225. Kuno Y., Abe A., Emi N., Iida M., Yokozawa T., Towatari M., et al. Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12)(q22;p12). Blood 2001, 97:1050-1055.